Primary Care

Do you generally feel they work well? Have patients tried using this a few days before an activity, such as skiing? Especially for otherwise healthy, ...

1 Answer available

Do you recommend adjusting the duration of a drug holiday based on the specific bisphosphonate used when treating osteoporosis?

1 Answer available

How do you approach managing nausea and GI side effects when initiating methotrexate?

5 Answers available

Is it better to give dose 2 of the mRNA 2024-2025 Covid-19 vaccine at month 2 or month 6 after dose 1 in moderately immunocompromised patients?

Is there any data to suggest one time-frame is better than the other? The CDC states give "2024–2025 Dose 2 (Moderna, Novavax or Pfizer-BioNTec...

1 Answer available

Would you consider utilizing transdermal estrogen for HRT to treat severe hot flashes in a patient with SLE and a history of thrombosis x2 and positive lupus anticoagulant, but negative aCL/B2GP1 abs?

Would concomitant use of a DOAC ease any concerns?

1 Answer available

How do you approach management of osteoporosis in patients post lung transplant?

1 Answer available

What circumstances would drive you to consider using an oral IL-23 inhibitor over parenteral options for the management of psoriasis and/or psoriatic arthritis?

This question is part of a collaboration with RheumMadness and is specifically in reference to: Bissonnette et al., PMID 38324484

2 Answers available

Would you stop denosumab in a patient with chronic kidney disease if they develop asymptomatic hypocalcemia after the injection?

4 Answers available

What is your experience with using anabolic therapy for treatment of osteoporosis in patients with EtOH cirrhosis and is one agent preferred over another (PTH analogue vs Evenity)?

Lack of large scale efficacy or safety data for PTh analogue or Evenity in this patient population.

2 Answers available

Is it safe to continue administering Prolia per schedule for osteoporosis treatment shortly after a patient has undergone extensive spinal surgery?

2 Answers available

What is your treatment approach for pregnant patients with IgA nephropathy who have worsening proteinuria during the first trimester?

1 Answer available

Would you continue Forteo treatment past the recommended 2 years if T scores remain low and procollagen (P1NP) is elevated and if so, how would you monitor response?

1 Answer available

What are your practice recommendations regarding live vaccinations in infants/children of women who are currently on DMARDs and are breastfeeding?

Does the recommendation change based on the DMARD?

1 Answer available

How do you approach the management of recurrent episcleritis in a patient with RA that is otherwise well-controlled?

No active joint disease, patient on Hydroxychloroquine and Cimzia. Normal ESR/CRP.

1 Answer available

How do you approach management of patients with psoriatic arthritis who have significant improvement in skin disease, but ongoing inflammatory arthritis despite multiple DMARDs and/or biologics?

3 Answers available

Do you recommend genetic screening for FMF in asymptomatic first-degree relatives with a strong family history (multiple family members, severe/refractory disease)?

1 Answer available

Would you order a repeat DEXA scan 1 year later for a kidney transplant patient who had an initial DEXA scan within the first 6 months post-transplant showing osteopenia but no history of fractures, and who has been stable on glucocorticoid-free immunosuppressive therapy?

2 Answers available

How do you determine osteoporosis treatment response when patients have discrepant DEXA scan results during monitoring (eg improved BMD of the hip and spine but worsening BMD of the femoral neck)?

1 Answer available

How do you reduce the risk of contralateral fracture in a patient with atypical femur fracture from prolonged bisphosphonate use?

Do anabolic agents have a role?

1 Answer available

Would you recommend avoiding use of bimekizumab in patients at higher risk of fungal infections such as patients with diabetes who are on SGLT-2 inhibitors which also increase the risk of fungal infections?

How will you counsel patients about the risk and what strategies will you use to mitigate the increased risk of fungal infections seen in the BE COMPL...

2 Answers available

How would you manage a patient with progressive/refractory molluscum contagiosum who is well controlled on methotrexate for seropositive rheumatoid arthritis?

Are you aware of any data regarding relative risk of molluscum contagiosum infection in reference to DMARDs/biologics?

1 Answer available

How frequently do you monitor for hypocalcemia in patients on romosozumab?

1 Answer available

How would you approach management of a patient with longstanding history of SLE, but having active psoriasis?

SLE manifestations include arthralgias and cytopenias which are stable. Previously did well on methotrexate, but developed GI side effects. HCQ is on ...

3 Answers available

Would you try combination ketorolac and cortisone injections in a patient with severe knee OA who refuses surgery and had partial responses to injections of cortisone and ketorolac separately?

2 Answers available

Would you consider using Evenity in an elderly patient with rate controlled atrial fibrillation without history of MI or CVA?

1 Answer available

Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?

2 Answers available

How would you approach management of a patient who develops squamous cell skin cancer while on abatacept?

Patient has had previous failure of methotrexate. Would you switch to alternative (TNFi or Rituximab) or continue abatacept with regular dermatology...

2 Answers available

Would you escalate treatment for a patient with Crohn disease with changes suggestive of chronic sacroiliitis on MRI but without bone marrow edema or effusion that suggests active inflammation?

2 Answers available

How do you manage osteoporosis treatment following parathyroidectomy for primary hyperparathyroidism?

1 Answer available

Does the presence of psoriatic arthritis affect your decision to use an anti-IL-17 or IL-23 drug in your psoriasis patients?

3 Answers available

How would you manage active psoriasis and psoriatic arthritis in patient on Rituximab and prednisone for MPO positive vasculitis?

The patient has ongoing inflammatory arthritis despite methotrexate, apremilast, and jak inhibitor trials.

1 Answer available

How long do you maintain patients with anti-synthetase syndrome on Rituximab?

The patient was treated with two doses of Rituximab and on MMF. Now with stable lung function and normalized CK.

2 Answers available

Do you prefer using losartan in your patients with hypertension and gout due to its uricosuric effects?

2 Answers available

Would you consider PTH analogue in a patient with mildly elevated PTH?

2 Answers available

Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?

1 Answer available

What are some of the biggest challenges you run into when patients transition from pediatric to adult care?

1 Answer available

Do you recommend adjusted adult cancer screening for patients who have been on long term biologics and/or tsDMARDs since childhood?

1 Answer available

Should HCQ be continued in an asymptomatic SLE patient who has received renal transplant?

If a patient has received a kidney transplant for SLE-LN and is stable and doing well. Managed by their transplant team and on chronic immunosuppressi...

2 Answers available

What are some strategies to help teach patients transitioning from pediatric to adult care to become more independent with respect to their care and less dependent on their caregivers?

1 Answer available

What is your treatment approach for a young female who has an idiopathic small right elbow effusion with synovial thickening that has resulted in limitation in her range of motion?

1 Answer available

How would you approach potentially tapering maintenance mycophenolate mofetil in a patient with a history of class IV LN that has been in remission for >5 years?

The case prompting the question is a female in her late teens who was diagnosed with Class IV LN at her prepubescent age and was treated with HCQ and ...

1 Answer available

Do you recommend uric acid lowering therapies for asymptomatic hyperuricemia in chronic kidney disease?

1 Answer available

When do you recommend using trabecular bone score (TBS) for managing osteoporosis?

1 Answer available

How would you counsel a patient with systemic sclerosis who wants to consider microneedling on the face or other skin which is not clearly involved with scleroderma?

1 Answer available

What is your approach for severe SCLE in patients unable to tolerate HCQ?

3 Answers available

Do you recommend avoidance of vaginal estrogen in patients with SLE?

What factors do you discuss when counseling the patient?

2 Answers available

How do you counsel patients with RA stable on csDMARDs on whether to attempt tapering or not?

While remission rates after lowering or discontinuing therapy are lower, there is still a population of patients who do not require full-dose therapy ...

2 Answers available

Are there any concerns with live vaccine innoculation and patients who are on denosumab?

1 Answer available

When transitioning from anabolic agent to denosumab, do you stop teriparatide 1 day prior to transition and romosozumab 1 month prior to transition?

1 Answer available

How do you approach medication management in patients with RA when transitioning from csDMARD triple therapy to anti-TNF?

Which csDMARD do you taper in order, and is there a tapering strategy (duration/dose)?

2 Answers available

Are you comfortable with using NSAIDs in a patient on methotrexate for inflammatory arthritis?

Given the drug-drug interaction, do you monitor more closely for methotrexate toxicity, counsel on symptoms of methotrexate toxicity, or avoid the com...

2 Answers available

What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?

1 Answer available

How would you approach management of a young male patient with discoid lupus who has had minimal response to hydroxychloroquine (and subtherapeutic whole blood levels) who continues to use tobacco products?

2 Answers available

Do you combine methotrexate and leflunomide for the treatment of RA?

3 Answers available

If a patient who has tolerated allopurinol for a prolonged period of time is subsequently found to be positive for the HLA-B*58:01 gene, how would you manage urate-lowering therapy thereafter?

1 Answer available

Would you transition a patient with axial spondyloarthritis to a biologic if their axial symptoms were controlled with an NSAID, but they also required a PPI to control dyspepsia/GERD caused by the NSAID?

1 Answer available

Do you prefer allopurinol or febuxostat for patients with chronic kidney disease who are receiving treatment for asymptomatic hyperuricemia?

4 Answers available

Do you feel comfortable using Jak inhibitors in patients with a strong family history of CAD, but no other risk factors?

How do you counsel patients in this scenario?

1 Answer available

Do you utilize serial MRI imaging in patients with axial spondyloarthritis to ensure good disease control or do you rely on symptoms and physical exam to assess treatment response?

1 Answer available

What treatments have you found most effective for cholestatic pruritus?

I have a patient with recently diagnosed primary biliary cholangitis/cirrhosis (PBC) with SSc. Her laboratory values are within normal limits, but end...

1 Answer available

Do you recommend a particular antiresorptive/anabolic agent for patients who are at high risk for fractures but have high risk of osteonecrosis of the jaw?

3 Answers available

Is there a role for the use of transient elastography (FibroScan) to monitor liver fibrosis in patients on long term methotrexate?

3 Answers available

How do you approach medication management in biopsy-proven pulmonary sarcoidosis with disease stable for over 2 years on hydroxychloroquine and low dose prednisone?

Do you discontinue HCQ?

2 Answers available

What is your approach for cancer screening for elderly onset RA?

1 Answer available

Would you transition from denosumab to anabolic agents in patients who are in urgent need for extensive dental work?

2 Answers available

What is your approach to a patient on long-term denosumab who now requires multiple invasive dental procedures?

2 Answers available

Are there situations in which you treat calcinosis cutis that is not symptomatic for the patient?

Given the lack of efficacy of most treatment options, do you generally try to treat calcinosis cutis that is not bothering the patient even if it is q...

2 Answers available

Do you avoid hyaluronic acid injections in patients with chondrocalcinosis on imaging?

2 Answers available

What is your approach to tapering therapy in patients with pulmonary sarcoidosis who are asymptomatic with stable pulmonary function and imaging?

1 Answer available

Would you escalate therapy in a patient with rheumatoid arthritis without synovitis, but a new rheumatoid nodule?

Do you consider the appearance of a new rheumatoid nodule as a sign of RA activity?

1 Answer available

Are there certain patients in whom you would avoid initiation of ULT during an acute gout flare?

This question is part of a collaboration with RheumMadness and is specifically in reference to: ULT During Gout Flare.

3 Answers available

What is your approach to work up for patients referred for early onset osteoarthritis?

1 Answer available

How often should lupus anticoagulant be checked in patients with SLE if prior was negative or if prior was positive?

1 Answer available

Would you uptitrate methotrexate dosing when a patient flares on a TNFi and methotrexate 15 mg weekly?

2 Answers available

How would you manage a middle-aged patient with Paget's disease who received one dose of zolendronic acid 2 years ago, currently suppressed CTX, normal bone-specific Alkaline phos, and a recent hairline fracture in the thoracic spine?

Is there any data on the use of anabolic agents in Paget's disease?

2 Answers available

How would you approach a finding of osteoporosis (Z score -4.5) in a recently postpartum patient who had DEXA sent for long-term low-dose glucocorticoid use?

The patient is actively breastfeeding.

1 Answer available

How do you determine duration of therapy for patients who have responded well to voclosporin therapy?

How do you monitor response and what do you consider a satisfactory response? Do you aim for a certain threshold of proteinuria?

3 Answers available

Is there any evidence regarding bone density gains/fracture reduction in the setting of treatment with romosozumab after a two year course of teriparatide?

Many patients are interested in romosozumab for "maximizing bone gain" and preventing future fractures. Some have had anabolic therapy with teriparati...

1 Answer available

How do you make the decision to empirically treat for GCA when a patient is referred but cannot be immediately seen in clinic?

When a PCP calls with concern for GCA and is wondering whether to start empiric steroids what data do you prioritize to make that decision and do you ...

4 Answers available

How do you approach discussing the pill burden of voclosporin with patients who already have to take a regimen such as MMF+HCQ+ACEi and possibly more?

2 Answers available

How do you counsel patients on the risks and benefits of an IL-23 agent versus an IL-17A or IL-17A/F agent?

What side effects do you highlight in conversation with them? How do you approach toxicity monitoring?

2 Answers available

What dose and duration of steroid therapy do you employ while starting mycophenolate in an outpatient with relatively stable CTD-ILD?

Do you ever start mycophenolate without steroids?

1 Answer available

What range of musculoskeletal complaints have you seen with romosozumab use?

1 Answer available

Do you prefer celecoxib over a nonselective NSAID in patients with chronic kidney disease?

4 Answers available

Do you delay pegloticase in a patient with an active gout flare?

2 Answers available

What is your approach to counseling patients regarding re-initiation of anti-TNF therapy after completion of treatment for non-disseminated pulmonary histoplasmosis?

Would it be safe to resume and if so, when?

2 Answers available

How do you plan to use canakinumab for the treatment of gout?

2 Answers available

Would you consider teriparatide use in a patient with prior radiation therapy, given that the black box warning regarding osteosarcoma risk has been removed by the FDA?

1 Answer available

For how long do you recommend treatment for latent tuberculosis prior to initiation of anti-TNF therapy?

6 Answers available

Would you consider PTH-analog therapy in a woman with osteoporotic vertebral fractures who has asymptomatic non-obstructive renal stones and normal 24-hour urine calcium level?

2 Answers available

How do you monitor patients with incidentally found high titer anti-smooth muscle antibodies without stigmata of liver disease?

3 Answers available

How long do you continue PJP prophylaxis in a patient with GPA who is able to wean steroids and remains only on rituximab for maintenance therapy?

1 Answer available

How would you manage gout with hyperuricemia >10 mg/dl despite the maximum dose of allopurinol plus probenecid and a prior allergic reaction to pegloticase?

2 Answers available

How do you time Evenity after completion of Forteo?

1 Answer available

Do you restrict topical diclofenac use in your patients with chronic kidney disease?

3 Answers available

How do you approach monitoring when using combination JAK inhibitors and methotrexate in RA?

1 Answer available

Would you use romosozumab in a patient with a cardiovascular event more than 2 years prior?

4 Answers available

What do you recommend to patients when they are having an acute flare of fibromyalgia symptoms?

1 Answer available

What are magic mouthwash alternatives that you would recommend?

There was a recall on viscous lidocaine and many of our patients cannot find it. What would you recommend as alternatives?

9 Answers available

What is your approach to maintenance treatment in a patient with Sjogren's who received rituximab for mononeuritis multiplex?

And how would you monitor response?

1 Answer available

Do you recommend osteoporosis medication in postmenopausal females on anastrozole with very low Vitamin D (4.5)?

After replacing Vitamin D, what will be your first treatment of choice? Labs including ALP and calcium levels are normal. T scores are -3 or above. Th...

1 Answer available

How do you counsel patients with non-statin associated inflammatory myopathies about statin use?

1 Answer available

What is your approach to monitoring for hepatic fibrosis in chronic methotrexate use?

Do you frequently order liver biopsies for these patients?This question is part of a collaboration with RheumMadness and is specifically in reference ...

2 Answers available

Do you always aspirate effusions in patients with knee osteoarthritis prior to injecting hyaluronic acid?

2 Answers available

What is your approach to nephrology referral for patients with lupus nephritis?

Do you refer all patients with suspected LN, patients with confirmed LN, or patients with specific features (not responding to usual therapy, certain ...

3 Answers available

Do you recommend Vitamin D and omega 3 fatty acid supplementation for prevention of autoimmune disease?

This question is part of a collaboration with RheumMadness and is specifically in reference to: Prevention of Autoimmune Disease: Vitamin D and O...

2 Answers available

Are there patients with gout in whom you would choose febuxostat first line over allopurinol for urate lowering therapy?

This question is part of a collaboration with RheumMadness and is specifically in reference to: Allopurinol vs. Febuxostat

1 Answer available

How do you counsel patients who prefer to continue TNFi therapy indefinitely for rheumatoid arthritis despite long-standing remission?

Do you advocate to taper the TNF-i or simply continue to monitor for long term adverse events? This question is part of a collaboration with Rheu...

3 Answers available

After completing 12 months romosozumab, what is the next best treatment option for patients with severe osteoporosis, high risk for fracture, and normal kidney function?

1 Answer available

What is your approach to practical monitoring of lupus disease activity in clinical practice?

What disease activity index do you find more useful and most practical in a busy clinical setting? How often do you assess it?This question is part of...

1 Answer available

How do you counsel patients on the use of topical nitroglycerin for Raynaud's?

What formulation of topical nitroglycerin do you use?

1 Answer available

How do you approach ongoing screening for TB in patients with a history of treated latent TB, but who have ongoing use of DMARDs and/or biologics given Quantiferon testing and PPD can remain positive?

How do you approach ongoing screening for TB in patients with history of treated latent TB, but have ongoing use of DMARDs and/or biologics given quan...

1 Answer available

How do you counsel patients on the benefits of diet and exercise in OA in a way that motivates them to comply?

This question is part of a collaboration with RheumMadness and is specifically in reference to: Exercise in Knee OA

1 Answer available

Do you typically screen every patient with headaches after the age of 60 with ESR?

6 Answers available

Would you consider anabolic osteoporosis therapy in a young adult male with multiple non-traumatic vertebral compression fractures and low bone density for age (Z-score -2.6)?

A male patient in his 30s with two lumbar compression fractures (non-traumatic) and a Z-score of -2.6 in the spine, Z-score -0.5 in hips. History of 3...

1 Answer available

What is your approach to transitioning an SLE patient from a pregnancy incompatible regimen to pregnancy compatible regimen?

For example, when switching from MMF to azathioprine, do you overlap the treatments as you lower the dose of one and add the other?

3 Answers available

When do you consider stopping denosumab when a patient with osteoporosis is otherwise tolerating it without issues?

Assuming follow-up IV bisphosphonate x2 infusions to prevent rebound fractures

5 Answers available

Do you avoid the use of hydroxychloroquine in patients with psoriasis and/or psoriatic arthritis?

1 Answer available

Do you have concerns with the use of oral contraceptives in patients on JAK inhibitors given the black box warning for thromboembolic events?

How has this impacted your counseling and management?

2 Answers available

Any concern for lupus flare in patients undergoing laser hair removal?

2 Answers available

How do you approach treating and monitoring sarcoidosis manifested by maxillary bone/teeth loss without other symptoms?

3 Answers available

What is your approach to treating osteoporosis in patients post bariatric surgery?

Are oral bisphosphonates contraindicated with all types of bariatric procedures?

3 Answers available

What is your approach to leflunomide and statin use in RA patients?

Is the interaction considered severe?

2 Answers available

Would you continue Jak inhibitor therapy in a patient with long standing, previously refractory RA in their 60s who was found to have stenosis of the left common femoral artery and no other history of arteriosclerotic disease?

1 Answer available

Do you counsel your patients on the potential decreased effectiveness of oral contraceptives while on Sarilumab?

If so, do you routinely recommend use of an additional form of contraception?

1 Answer available

How would you manage a patient with SLE that has a remote history of positive anti-phospholipid antibodies with a current DVT and now completely negative APLs?

Would you still plan for lifelong anticoagulation in this scenario?

1 Answer available

Would you consider the use of doxycycline or minocycline in the management of RA?

4 Answers available

How do you approach an obese patient on long-term methotrexate with normal liver tests in terms of workup for underlying fatty liver?

Would you start with a baseline ultrasound and then pursue further workup such as fibroscan if fatty liver is present, or other?

1 Answer available

How do you approach GI prophylaxis (e.g., PPIs, H2 blockers) in patients on long-term NSAIDs?

1 Answer available

How would you approach rheumatoid arthritis treatment for widespread large rheumatoid nodules but no active synovitis or subjective joint pain?

Patient taken off methotrexate.

2 Answers available

Would you increase the hydroxychloroquine dose to more than 5 mg/kg/day in a compliant patient with active non-organ threatening lupus (skin+joints) if serum hydroxychloroquine is not at goal until you reach an acceptable concentration?

3 Answers available

At what point do you consider a patient to have relapsing PMR?

How much cumulative prednisone exposure do you tolerate and how many attempts at tapering will you pursue before considering addition of a steroid spa...

4 Answers available

What is your approach to patients with SLE who develop a rash after hydroxychloroquine initiation?

3 Answers available

How do you approach follow up of young patients with isolated +ANA, but no current clinical signs or symptoms of SLE?

This question is part of a collaboration with RheumMadness and is specifically in reference to: Antibodies Before SLE.

6 Answers available

Can anabolic agents be used in a patient with history of radioactive iodine treatment for hyperthyroidism?

1 Answer available

Would you switch a patient with glucocorticoid induced osteoporosis to romosozumab if a patient sustained a fragility fracture 1 year into treatment with teriparatide?

1 Answer available

Do you consider anti-viral prophylaxis in patients taking JAK inhibitors who have recurrent uncomplicated Zoster infection, but would prefer not changing therapy?

2 Answers available

What is your approach for disease activity monitoring in patients with sarcoidosis?

1 Answer available

When do you start bisphosphonates empirically, irrespective of DEXA results, in patients going on chronic glucocorticoids?

1 Answer available

Where do you place romosozumab in your treatment sequence for osteoporosis management?

4 Answers available

Is monitoring for fetal heart block recommended in pregnant patients with only slightly elevated SSA?

2 Answers available

Have the results of the ancillary study of the VITAL trial, demonstrating that Vitamin D3 supplementation did not reduce the incident rate of fractures in generally healthy midlife and older adults, changed how you prescribe Vitamin D?

PMID 35939577

2 Answers available

How do you manage patients with SLE undergoing assisted reproductive therapy with estrogenic effects?

2 Answers available

At what point would you consider anticoagulation in a pregnant patient with lupus nephritis and non-nephrotic range proteinuria?

3 Answers available

Do you continue belimumab throughout pregnancy?

4 Answers available

What is your approach to treatment of skin-limited cryoglobulinemic vasculitis in patients with Sjogren's syndrome who lack evidence of neurological or renal involvement?

1 Answer available

How would you approach choosing osteoporosis treatment in a patient with a T score -3.3 in lumbar spine and no prior fracture history who has squamous cell cancer and received radiation therapy?

1 Answer available

How will you approach tapering sarilumab in patients with PMR in remission?

After what interval of sustained remission will you attempt to taper, and will you do so by first widening the dosing interval?

2 Answers available

How do you manage recurrent urticarial lesions in a patient with underlying connective tissue disease that is otherwise well-controlled?

3 Answers available

How will you adjust your approach to steroid taper in patients with PMR also on sarilumab?

2 Answers available

What baseline and ongoing testing do you recommend for patients with PMR who are going to be on a prolonged steroid taper?

Do you universally perform baseline DEXA and Hgb A1C? How often are you obtaining routine labs?

2 Answers available

How do you approach the timing of Rituximab during pregnancy in a patient with life or organ threatening autoimmune disease?

3 Answers available

What would be your next step in treating a patient with osteoporosis who developed AFF on denosumab and who then completed one year of romosozumab?

3 Answers available

Would you start anticoagulation in a patient with provoked blood clot in the past now with labs done for rheumatological reasons showing triple positive APLA?

If so, would you start immediately or wait for the second set of labs to confirm before initiating blood thinners?

3 Answers available

Do you stop TNF inhibitors during the third trimester of pregnancy?

2 Answers available

For a patient with osteopenia or osteoporosis, how long can intravenous zoledronic acid be maintained if there are not adverse events?

1 Answer available

What is your approach to patients with severe sicca symptoms and history of B Cell lymphoma?

Patient has received treatment with Rituximab and is taking hydroxychloroquine.

1 Answer available

What is your approach to tapering chronic steroids in patients who are at high risk of HPA suppression?

For example, patients who have been maintained on 5mg of prednisone for years without previous tapering attempts and the rheumatic disease is not acti...

1 Answer available

How do you approach pre-conception counseling in males who are on medications for which there is limited or no data such as Jak inhibitors, apremilast, or belimumab?

2 Answers available

Would atypical fractures of the hip in a parent (treated with bisphosphonate) be considered when calculating the FRAX score for a patient with osteopenia?

2 Answers available

How do you approach monitoring for lymphoproliferative disease in Sjogren's patients?

2 Answers available

How would you approach a woman with APLA but no thrombosis/APLS, a history of ITP without bleeding who is now pregnant?

2 Answers available

Would one year of steroids for JRA during teen years (with subsequently well-controlled autoimmune disease) be sufficient to explain a vertebral T score of -4.4 of a woman in her early 50s without any other risk factors?

1 Answer available

Would you consider a biologic or JAK inhibitor to manage active PsA in a patient on chronic antibiotic therapy if they had previously failed all conventional DMARDs (including apremilast)?

Patient is on antibiotics for chronic spinal hardware infection.

1 Answer available

Would you have a patient temporarily discontinue methotrexate while receiving a FAST or FAST FORWARD regimen for breast irradiation?

The patient is on a dose of 22 mg of methotrexate weekly for severe rheumatoid arthritis. If you would discontinue the methotrexate, how long would y...

1 Answer available

In patients undergoing MRI evaluation for inflammatory back pain, how long do you recommend they hold NSAIDs prior to imaging?

3 Answers available

In a patient with neurosarcoidosis who required infliximab for initially refractory symptoms but is now stable, how do you decide on the optimal time to de-escalate therapy?

1 Answer available

Do you ever taper or stop urate lowering therapy in patients who have had no gout flares and serum urate persistently below 6 mg/dl?

In patients with CKD, does urate lowering therapy have an effect (positive or negative) on progression of CKD?

1 Answer available

Do you recommend routine genetic screening (i.e., periodic fever panel) in a pediatric patient where you strongly suspect a periodic fever syndrome?

2 Answers available

How do you approach treatment of PMR in a patient who has had avascular necrosis of the hip after starting steroids?

1 Answer available

How do you decide when to try stopping hydroxychloroquine in patients with erosive osteoarthritis?

1 Answer available

How do you monitor patients with cutaneous lupus for progression to SLE?

Do you do blood work? Or do you rely on review of systems?

1 Answer available

What is your approach to management of chronic recurrent parotitis in patients with Sjogren's Syndrome?

2 Answers available

What is your approach to management of persistent painless salivary gland swelling/sialadenitis in patients with Sjogren's?

No evidence of malignancy on serial CT scans.

2 Answers available

How do you manage calcium and vitamin D replacement in scleroderma and myositis patients with dysphagia and malabsorption?

1 Answer available

How do you approach urate-lowering therapy in patients with advanced chronic kidney disease?

What doses of allopurinol do you use, and how frequently do you titrate the dose?

1 Answer available

What is your approach to treating premenopausal woman with OI with a new compression fracture?

2 Answers available

What is your approach to monitoring a patient with SLE who has persistent hypocomplementemia on hydroxychloroquine, but clinically has resolution of cutaneous symptoms and no other internal organ manifestations of disease?

(C3 just below normal, C4 undetectable)

2 Answers available

How do you approach methotrexate management around vaccines other than COVID and influenza?

Data is clear that we should hold methotrexate at least one week after COVID and flu vaccines. How do you approach methotrexate management around Shin...

1 Answer available

How would you approach the management of a patient with tophaceous gout who consistently has a serum uric acid under 5 on allopurinol but continues to experience gout flares?

2 Answers available

Would you consider teriparatide in a postmenopausal woman with normal DEXA who had a traumatic humerus fracture three months prior with surgical intervention and plain Xrays showing only partial healing?

2 Answers available

At what point, if at all, do you decrease the frequency of or discontinue pegloticase infusions after achieving persistently low serum urate levels?

1 Answer available

What treatment would you use in a patient with osteoporosis on denosumab for 10 years who develops ONJ at a site of an old implant?

1 Answer available

How do you approach transaminase elevations with use of allopurinol in gout?

Do you rechallenge with lower dose? What is your tolerance for mild persistent transaminitis?

1 Answer available

How often do you monitor labs in patients taking methotrexate?

4 Answers available

How would you treat inflammatory arthritis in a patient with Sjogren's syndrome and ILD (on mycophenolate) that is not responsive to hydroxychloroquine?

1 Answer available

How do you approach treating mild hypercalcemia in patients with sarcoidosis?

1 Answer available

How do you approach long term management of glucocorticoid-induced osteoporosis in patients who develop osteonecrosis of the jaw on antiresorptive agent?

2 Answers available

Do you recommend starting aspirin for a patient with ESKD secondary to lupus nephritis with detected antiphospholipid antibodies on pretransplant workup but no history of a thrombotic event?

3 Answers available

Would you start anticoagulation in a patient with a history of CVA 1 year ago and high risk APL profile who was never started on anticoagulation, but is now presenting for follow up and without recurrent thrombotic events?

The patient has no known history of autoimmune disease.

4 Answers available

How would you manage tubulointerstitial nephritis and renal tubular acidosis (RTA) in a patient with Sjogren's who is pregnant?

2 Answers available

What is the optimal timing for Zoster vaccine administration for a patient who recently recovered from herpes zoster infection and is now planning to start B-cell depletion therapy?

1 Answer available

Is there any contraindication to the use of ezetimibe in patients with a history of statin induced necrotizing myopathy?

2 Answers available

Would you escalate treatment for a clinically stable/asymptomatic lupus patient with persistent leukopenia/neutropenia, already on hydroxychloroquine?

6 Answers available

What would be your approach to a SLE patient who is triple APS positive, has no prior VTE/obstetric events, is stable on HCQ and low dose aspirin, and wants to become pregnant?

2 Answers available

How do you counsel patients regarding alcohol intake when prescribing DMARDs other than methotrexate?

Such as Leflunomide, Sulfasalazine, Mycophenolate or Azathioprine, since all of these medications have potential to cause liver enzyme elevation and i...

1 Answer available

How do you approach management of patients with active RA and recurrent non-severe C.diff?

(Patient with active RA despite hydroxychloroquine)

1 Answer available

How would you approach a patient who has well controlled SLE on HCQ but develops cotton wool spots on routine ophthalmologic screening?

3 Answers available

How do you manage injection site reactions in patients on subcutaneous biologics such as TNF inhibitors?

In what cases do you discontinue the medication?

2 Answers available

How long do you expect gastrointestinal side effects of leflunomide to persist after stopping treatment?

2 Answers available

What indicators do you use to determine whether a patient is having a favorable or unfavorable response to nintedanib?

When adding nintedanib what sort of treatment course do you counsel the patient on? Do you plan to continue it indefinitely as long as the patient tol...

3 Answers available

When tapering moderate to high doses of long term steroids do you routinely monitor for adrenal insufficiency?

Do you attempt to taper fully or maintain at a low dose?

2 Answers available

How would you manage a patient with osteoporosis on denosumab who develops significant renal insufficiency where it is difficult to continue denosumab due to increased risk of hypocalcemia (i.e. eGFR in the low 20’s)?

1 Answer available

Do you use apremilast in combination with biologic DMARDs for psoriatic arthritis and/or psoriasis?

Are there ways to overcome barriers in insurance coverage of this combination of treatments?

2 Answers available

In an RA patient with positive RF and CCP abs who is stable on TNFi biologic, how would you approach incidentally found low titer positive DsDNA abs?

Would you switch to a non TNFi biologic or continue current regimen with careful monitoring for evolution of lupus manifestations?

2 Answers available

Do you combine oral and topical NSAIDs for pain relief?

2 Answers available

What is your approach to screening for complete heart block in an asymptomatic pregnant patient with negative SSA and positive SSB antibodies?

1 Answer available

Do you routinely advise patients waiting for a kidney transplant to seek referrals at multiple institutions to decrease waiting time?

1 Answer available

What is your approach to patients with positive anti-CCP, negative RF and tobacco use, but no current signs of active rheumatoid arthritis?

1 Answer available

How often should you screen for lymphoma in patients with primary Sjogren's syndrome?

1 Answer available

What kinds of dental work do you particularly worry about and try to avoid in patients on bisphosphonates?

2 Answers available

Do you recommend patients continue folic acid for a few weeks after methotrexate discontinuation?

1 Answer available

In a patient with APS and obesity during pregnancy when switched to LMWH, do you cap the dose of dalteparin as per manufacturers labeling at 18,000U per day or do you use weight based dosing?

1 Answer available

How do you specifically counsel patients on conservative measures such as hand warming in the treatment of SSc associated digital ulceration?

In addition to the usual pharmcotherapy (CCBs, etc.)

1 Answer available

How do you approach the use of hydroxychloroquine in patients with a history of visual field defect from another cause such as macular degeneration or diabetic retinopathy?

3 Answers available

Do you use IL-1 inhibitors to prevent flares of gout or CPPD in patients who experience flares despite prophylaxis with colchicine, NSAIDs, and/or low-dose prednisone?

2 Answers available

What treatment options do you recommend to patients with microstomia secondary to scleroderma?

Have you tried hyaluronidase?

2 Answers available

Is febuxostat a safe alternative for patients who are HLA-B*58:01 positive and of Han Chinese descent?

1 Answer available

How do you counsel patients regarding contraception use while taking mycophenolate/mycophenolic acid?

2 Answers available

In a patient who fractures after several years of denosumab therapy, would you wait 6 months after the last denosumab injection to start an anabolic agent or could start an anabolic agent sooner?

1 Answer available

Are there specific recreational activities or exercises you recommend patients with ankylosing spondylitis avoid?

1 Answer available

Would you avoid the entire class of bisphosphonates if a patient develops an allergic reaction, or would you consider the use of an alternative bisphosphonate?

2 Answers available

What are some explanations for the persistent renal outcome disparity gaps affecting certain minority groups of patients with pediatric SLE despite improvement in overall renal outcomes?

What would you suggest to help address these disparities in our own practices?

2 Answers available

How would you approach a low to moderate titer of one of the APLS antibodies in a patient with a strong family history but no personal history of thrombosis?

Although testing was not indicated, what do u do with these results? Other hypercoagulability work up negative

2 Answers available

How do you approach recurrent costochondritis in an SLE patient with nephritis who is otherwise controlled on MMF and HCQ but can't take NSAIDs?

2 Answers available

Is it ever appropriate to restart bipshosphonates following a drug holiday in a patient with a prior atypical hip fracture?

5 Answers available

What is your treatment approach to persistent chillblains lesions in the absence of systemic lupus?

1 Answer available

Would you discontinue anticoagulation in patients with antiphospholipid antibody syndrome, who have a remote history of thrombotic events and are now negative for pathogenic antiphospholipid antibodies?

Would the answer differ if the index event was arterial vs venous?

3 Answers available

What is your approach to the use of NSAIDs in patients with a history of gastric sleeve/bypass?

1 Answer available

How do you interpret elevations in ESR and CRP in the setting of increased BMI?

4 Answers available

When do you consider discontinuing Pegloticase in a patient with tophaceous gout who has had excellent response to therapy?

1 Answer available

How do you approach the work up for patients with fibromyalgia and hypermobility?

When do you refer to genetics? Does your approach change if they have an additional finding such as mitral valve prolapse or a prolapsed bladder/uteru...

3 Answers available

What is your approach to refractory erosive osteoarthritis?

Significant impact on ADLs and no response to doxycycline, hydroxychloroquine, sulfasalazine or methotrexate.

2 Answers available

What is your approach to patients with PMR on steroids over a prolonged initial course who start to experience weakness concerning for steroid myopathy?

1 Answer available

How do you approach methotrexate management in patients with rheumatoid arthritis and moderate NASH but no fibrosis per FibroSURE?

Continue MTX with monitoring of LFTs vs switching to another oral DMARD (aza, lef) vs GI for fibroscan?

1 Answer available

What is your approach to treating tophaceous gout in patients whose uric acid is below 5 prior to initiating uric acid lowering therapy?

1 Answer available

How do you approach adding colchicine to a patient who is on a stable statin regimen?

2 Answers available

How do you use colchicine for gout in patients with chronic kidney disease or end-stage renal disease on hemodialysis?

2 Answers available

Do you discontinue or adjust azathioprine when a patient develops elevated MCV after starting it?

When it seems fairly certain that this is a drug effect is it something that can just be monitored or requires a change in approach?

2 Answers available

Would you consider thrombophilia testing in a pregnant patient with VTE?

If work-up is sent and the patient is found to have a persistently positive antiphospholipid antibody, particularly lupus anticoagulant, would you con...

2 Answers available

How would you approach a young patient with a history of APLS and VTE, desiring hormone replacement therapy after oophorectomy?

Currently on nonwarfarin therapeutic anticoagulation

1 Answer available

For a patient who would benefit from an anabolic agent for osteoporosis, do you prefer romosuzumab over teriparatide in the absence of contraindications to either agent?

3 Answers available

How do you approach a potential drug holiday in a patient with osteoporosis who has had improvement in BMD after several years of denosumab therapy?

1 Answer available

Would you consider using a JAK inhibitor in combination with an IL 23 inhibitor in cases of severe psoriasis, psoriatic arthritis, or axial spondyloarthritis that is refractory to multiple biologic DMARDs?

2 Answers available

Do you ever consider using a higher dose of upadacitinib (30 mg daily) for rheumatoid arthritis in patients who fail to respond/partially respond to established dosing of 15 mg daily?

1 Answer available

How do you approach treatment of RA with methotrexate in a patient with treated Hepatitis C and normal liver function?

1 Answer available

How do you treat celiac disease associated inflammatory arthritis refractory to gluten free diet?

1 Answer available

Do you recommend allopurinol desensitization in gout patients who develop a rash on allopurinol therapy?

2 Answers available

Are there any concerns utilizing apremilast for psoriatic arthritis in patients who are also taking roflumilast for COPD?

1 Answer available

What bDMARD would you choose for a patient with RA with high infection risk and inadequate response to cDMARDs?

Infection risk being primarily chronic venous stasis ulcers

1 Answer available

What is your approach to discussing risk of adverse cardiovascular events in patients with RA whom you are considering starting a JAK inhibitor?

Data is mixed based on the results of ORAL surveillance, STAR-RA and nationwide cohort studies.

2 Answers available

Is there a role for low dose aspirin in a patient with AVN in four large joints who has underlying well-controlled SLE and positive APLs but no history of clots?

1 Answer available

How do you approach the continued use of TNF inhibitors in a patient with inflammatory arthritis who develops a positive dsDNA without clinical evidence of drug-induced lupus?

2 Answers available

How do you approach Covid vaccine counseling in patients with rheumatic disease and history of pericarditis/serositis?

1 Answer available

How do you approach treatment of osteoporosis in patients with CKD who develop a fragility fracture while on denosumab?

1 Answer available

Do you offer anticoagulation to patients with prior antiphospholipid antibodies detected in pregnancy without a history of pregnancy loss or thrombosis?

What is the risk of pregnancy loss in absence of anticoagulation? What would you suggest if the patient had anticoagulation in prior pregnancies and r...

3 Answers available

How do you approach tapering off JAK inhibitors in patients with rheumatoid arthritis who are in sustained remission?

3 Answers available

How do you weigh the risks of re-treatment with infliximab in a patient who has been off it for over a year?

2 Answers available

Do you recheck screening labs (ESR, BUN/Cr, urinalysis, ANA, etc) for patients with recurrent small vessel vasculitis of unknown origin with each flare?

1 Answer available

What is your approach to ongoing assessment and medication tapering in well controlled discoid lupus without systemic features?

3 Answers available

What is your approach to using apremilast for psoriatic arthritis in patients with history of depression?

1 Answer available

How do you assess potential fetal harm in patients who have unplanned pregnancy while taking teratogenic medications?

1 Answer available

How do you monitor a patient with scleroderma during pregnancy?

1 Answer available

How long would you consider the use of low-dose aspirin in a patient with SLE and high risk aPL profile (without a clinical event)?

1 Answer available

How do you approach the treatment of bullous cutaneous lupus?

When would you de-escalate therapy?

1 Answer available

Do you need to hold Humira (adalimumab) during radiation for breast cancer in a patient with psoriatic arthritis?

1 Answer available

Do you continue to routinely screen for renal involvement in a patient with established Sjogren's syndrome who otherwise has only sicca symptoms?

1 Answer available

How do you manage nausea in the setting of hydroxychloroquine use?

1 Answer available

When do you consider referral to hand surgery for management of joint deformity in RA?

2 Answers available

In a patient identified as having APLS because of recurrent pregnancy loss without history of thrombosis, but now has a new DVT/PE during pregnancy despite use of enoxaparin—for how long would you recommend anticoagulation?

Is it time limited since it may have been triggered by the pregnancy or is it indefinite since it is APLS associated?

2 Answers available

In a patient who completed 5 years of oral bisphosphonate and has a T score persistently in osteoporotic range, what factors help you decide whether it is appropriate to start a drug holiday vs. switch to an alternative agent?

1 Answer available

What is your approach to further workup, monitoring, and treatment of Sjogren's syndrome patients with positive cryoglobulins but no clear signs of vasculitis?

1 Answer available

Do you change management in patients that are taking bisphosphonates and develop atrial fibrillation?

1 Answer available

In patients who develop a VTE, what conditions do you consider as persistent, provoking risk factors, and at what point are they controlled enough to stop anticoagulation?

I.e., what constitutes well-controlled cancer, IBD, nephrotic syndrome, etc. What other diseases do you put in this category (obesity, autoimmune dise...

1 Answer available

Do you counsel your RA patients to hold their methotrexate dose for simple infections such as UTIs?

1 Answer available

What is your approach to treatment for patients with microscopic polyangiitis who have sustained remission at 6 months after induction rituximab?

Is there a role for monitoring for relapse or increased disease activity as opposed to scheduled dosing?

1 Answer available

Do you refer all patients with a Beighton score over 5 to genetics for further assessment?

2 Answers available

What drug class would you use to treat active psoriasis and psoriatic arthritis with axial involvement in patients on immunosuppression for other indications (e.g., tacrolimus for a liver transplant)?

1 Answer available

What have you found effective for the chronic fatigue that is often seen in patients with SLE or Sjogren's despite overall good disease control?

1 Answer available

Would you favor stopping hydralazine in a patient requiring it for refractory hypertension if they also have a high titer ANA in the absence of any SLE symptoms?

2 Answers available

In postmenopausal osteoporosis, would you switch to romosozumab (rather than a PTH/PTHrP analog) if a patient fractures while on denosumab?

1 Answer available

How long would you recommend that a patient continues guselkumab prior to deciding that the therapy is not effective?

In contrast to TNF inhibitors for psoriatic arthritis, which seem to peak and maintain response percentages, the DISCOVER-2 Trial (McInnes et al., PMI...

4 Answers available

How do you approach the use of bisphosphonates in reproductive-aged women?

1 Answer available

Despite the lack of evidence, do you utilize glucosamine and chondroitin sulfate for osteoarthritis?

2 Answers available

Does romosozumab need to be followed immediately by an anti-resorptive agent to preserve BMD gains, or could you consider a drug holiday?

1 Answer available

What is your experience with using extended release intra-articular steroid preparations, such as Zilretta in patients with osteoarthritis?

2 Answers available

How do you counsel young adults with antibody-negative necrotizing myopathy on prognosis and long-term monitoring/treatment?

How do you counsel young adults with antibody-negative necrotizing myopathy on prognosis, risk of recurrence, and long-term monitoring/treatment?

1 Answer available

When do you consider vascular imaging in patients with Raynaud's and what type of imaging modalities do you utilize?

1 Answer available

Do you escalate treatment for reactive lymphadenopathy in an otherwise stable and asymptomatic patient with lupus?

(assuming that the malignancy evaluation has been completed and the lymphadenopathy is confirmed to be reactive)

1 Answer available

Would you consider the use of low-dose naltrexone in patients with fibromyalgia and/or type 2 lupus symptoms?

4 Answers available

How do you approach CV risk assessment in RA patients when RA itself is associated with some degree of increased CV risk at baseline?

Recent articles regarding the use of JAK-Inhibition in RA have suggested to avoid in patients with increased CV risk. However, RA itself is cons...

2 Answers available

Would you recommend that a patient with stable coronary artery disease and well-controlled RA on a JAK inhibitor continue on their current therapy?

2 Answers available

Do you still plan to offer tofacitinib to RA patients over 65 if they have one or more additional CV risk factors?

2 Answers available

How do you counsel patients regarding the cardiovascular and cancer risks associated with tofacitinib?

2 Answers available

Would you anticoagulate recurrent venous thromboembolism in a patient with Ehlers Danlos syndrome?

How would the approach differ if the patient had a significant bleeding phenotype vs only minor bruising and mucosal bleeding?

1 Answer available

Would you consider using teriparatide beyond a cumulative maximum of two years now that the black box warning regarding osteosarcoma has been removed?

1 Answer available

Do you generally recommend low dose aspirin for patients with giant cell arteritis?

2 Answers available

Do you treat fibromyalgia in your practice or do you refer back to PCP after ruling out autoimmune inflammatory pathology?

3 Answers available

Do you repeat antiphospholipid antibody testing in a patient that previously met criteria for APLS?

If so, how long after diagnosis do you do so?

1 Answer available

Is there any utility in checking HLA-B*5801 in our Black and Asian patients who are already tolerating allopurinol?

1 Answer available

Would you advise a patient with quiescent vasculitis who flared with the first Covid mRNA vaccine to obtain an additional dose?

Would you suggest switching to a viral vector vaccine, such as J&J?

2 Answers available

What is your approach for gout flare prophylaxis in patients with diabetes and advanced CKD?

Preference for low dose steroids vs attempting colchicine?

1 Answer available

Is there a role for regular hepatitis and TB screening in patients on chronic immunosuppressive therapy in the absence of new risk factors or exposures?

1 Answer available

Should we recommend the COVID-19 booster vaccine to patients who had a DVT or any other complications such as hemolytic anemia or thrombocytopenia from prior vaccine doses?

2 Answers available

How do you counsel patients about the risk of osteonecrosis of the jaw with anabolic agents such as teriparatide or romosozumab ?

Would you hold these agents in the setting of invasive dental procedures?

1 Answer available

What has been your experience using apremilast to treat mild to moderate psoriatic arthritis not controlled with NSAIDs?

1 Answer available

Are there any known contraindications for IL-23 use in patients with psoriatic arthritis and CKD or ESRD?

1 Answer available

What lab markers are helpful for monitoring polymyalgia rheumatica patients on tocilizumab?

Since tocilizumab is known to normalize ESR/CRP, are there any markers/blood tests that may be helpful to check for PMR patients with question of exac...

1 Answer available

Do you hold tocilizumab for patients who are diagnosed with Covid and are with mild to moderate symptoms or non-hospitalized?

1 Answer available

What strategy do you use to determine the appropriate timing to resume osteoporosis therapy after a drug holiday?

2 Answers available

Do you ever consider treatment outside of the peripartum period in a patient with a history of obstetric APS?

i.e. obstretric APS without thrombosis or SLE

2 Answers available

Do you recommend EMG/NCS in all patients with clinical findings of carpal tunnel syndrome?

4 Answers available

Is it ever appropriate to reduce urate lowering therapy dose due to very low urate levels?

Are there implications of reducing urate too much?

1 Answer available

Is there a role for prednisolone over prednisone in rheumatic patients with hepatic impairment?

1 Answer available

Would you consider use of an oral bisphosphonate (such as alendronate liquid) in a patient with eosinophilic esophagitis?

1 Answer available

How would you approach osteoporosis management in a patient who fractures while on denosumab therapy?

Would you consider keeping the patient on denosumab or would switch to an anabolic agent?

1 Answer available

Do you screen for HLA-B*5801 prior to starting allopurinol in patients of backgrounds other than Asian or African-American?

Specifically in patients of Vietnamese background? An association has been shown between HLA-B*5801 and the risk of allopurinol hypersensitivity react...

1 Answer available

Given the "LDL Paradox", in which RA patients with the highest levels of inflammation can have ultra-low levels of LDL (<70), how do you approach initiation of statin therapy in these patients?

Dr. Charles-Schoeman presented data at ACR 21 showing that, paradoxically, there is a U-shaped relationship between inflammation and LDL levels in pat...

1 Answer available

How do you approach prophylaxis against glucocorticoid-induced osteoporosis in patients with end-stage renal disease on dialysis?

1 Answer available

What is your management approach for patients with Adult Onset Still's who are planning pregnancy?

1 Answer available

What is your approach to a patient with positive antiphospholipid antibodies who otherwise do not meet clinical criteria for APS?

What if the patient is triple-positive or has continued seropositivity on repeat lab testing? What is the appropriate interval of monitoring and does ...

3 Answers available

How do you counsel patients regarding the cardiovascular risk of febuxostat?

1 Answer available

Do you recommend COVID vaccination in patients with antiphospholipid antibody positivity or other prothrombotic states not on anti-coagulation?

1 Answer available

How do you interpret DXA results in cases where there is discordance between normal hip and spine BMD with abnormal one-third radius BMD?

2 Answers available

Do you consider low-dose aspirin for primary thromboprophylaxis in patients with high-risk antiphospholipid antibody profiles?

While low-dose aspirin for primary thrombosis prevention in aPL without APS is not typically recommended outside cardiovascular prevention guidelines ...

1 Answer available

How are you timing the third dose of the COVID-19 mRNA vaccine in patients on rituximab?

1 Answer available

How long would you treat with antimycobacterials before starting biologic DMARD in a patient with latent TB and active rheumatoid arthritis?

1 Answer available

What is your approach to a patient with rheumatoid arthritis and moderate disease activity on 25 mg of PO methotrexate?

Do you switch to SQ MTX, or is it best to add tx, such as a TNFi?

1 Answer available

In which patients with autoimmune or inflammatory conditions are you recommending a 3rd dose of the mRNA COVID vaccine?

2 Answers available

Is it ever reasonable to switch to a different TNFi as opposed to switching to an agent in a different class in a case of TNFi induced lupus or psoriasis?

In other words, do we think of TNFi induced lupus and TNFi induced psoriasis as a drug effect or a class effect?

1 Answer available

How long do you continue steroid-sparing agents such as tocilizumab for GCA once the disease is in remission off steroids?

1 Answer available

How do you approach NSAID use in patients on SSRIs?

Do you avoid due to the increased risk of GI adverse events?

1 Answer available

What disease activity measures do you find helpful in clinical practice for psoriatic arthritis/peripheral spondyloarthritis?

1 Answer available

How do you approach folate supplementation for methotrexate-related side effects?

3 Answers available

What is your approach to a patient with incidental radiographic findings of sacroiliitis without clinical inflammatory back pain?

2 Answers available

What is your approach to monitoring lipids in patients with rheumatic diseases such as RA and SLE and do you have a lower threshold to start lipid lowering agents compared to the general population?

2 Answers available

Is there a role for starting an anabolic agent in a patient that developed an atypical femoral fracture while on denosumab sooner than 6 months after the last denosumab dose?

Is there a role for earlier use of anabolic agents to promote bone healing in patients that develop AFFs?

2 Answers available

How do you determine when to transition off pegloticase to other uric acid lowering therapies?

1 Answer available

How would you approach localized lymphadenopathy in a patient with lupus whose symptoms are otherwise well-controlled?

2 Answers available

What is your approach to long-Covid/post-Covid syndrome in your practice?

2 Answers available

How would you counsel a patient who is interested in using supplements (such as fish oil or turmeric) as an adjunct to treatment of inflammatory arthritis?

3 Answers available

How do you approach monitoring of patients found to have a positive anti-dsDNA antibody without other clinical evidence of SLE?

1 Answer available

What is your methotrexate initiation strategy in DMARD-naive RA patients?

Specifically: starting dose, rapidity of up-titration, frequency of lab monitoring, frequency of office visits, and timing of assessment for treatment...

2 Answers available

Would you consider using a TNFi in a patient with a family history of demyelinating disease, in the absence of a personal history?

2 Answers available

How do you approach management of patients with inflammatory arthritis who are asymptomatic but develop radiographic progression?

1 Answer available

How would you advise patients with known stable autoimmune thrombocytopenia regarding the Ad26.COV2.S (Johnson & Johnson/Janssen) vaccine?

1 Answer available

How do you approach the use of low-dose aspirin for primary prevention in non-pregnant patients with SLE and positive aPL antibodies, without clinical criteria for APS?

Do you follow the 2019 EULAR Guidelines that SLE patients with asymptomatic, positive aPL should be on low-dose ASA?

1 Answer available

How do you transition to an anabolic agent in a patient who develops an atypical fracture while on denosumab?

1 Answer available

What is your threshold for number of alcoholic drinks per week before reconsidering prescribing methotrexate/leflunomide?

1 Answer available

How do you advise patients who had autoimmune diseases "triggered" by COVID infections on getting COVID vaccination?

E.g., inflammatory polyarthritis or inflammatory myopathy with onset within 2 weeks of documented COVID infection

1 Answer available

What is your strategy to prevent and treat constipation in patients initiating or receiving opioids?

What non-pharmacological interventions do you recommend? Do you routinely prescribe prophylactic laxatives to patients initiating opioids? How do you ...

3 Answers available

What is your approach to managing abnormal lipids in a patient on tocilizumab?

1 Answer available

What is your approach to a patient with an isolated positive rheumatoid factor, negative anti-CCP antibody, and no clinical or imaging evidence of rheumatoid arthritis?

3 Answers available

Do you eventually stop urate-lowering therapy in gout patients with CKD who start hemodialysis?

1 Answer available

How do you counsel patients on JAK inhibitors about the risk of venous thromboembolism, MACE, and cancer?

1 Answer available

Do you approach therapy differently for patients with a diagnosis of osteoporosis based on a fragility fracture rather than based on bone mineral density on DXA (assuming no secondary causes of osteoporosis)?

1 Answer available

Do you check pertussis serologies when sending labs for antiphospholipid syndrome?

2 Answers available

How do you approach therapy for severe osteoporosis after an initial 12 months of romosozumab?

1 Answer available

What would be your next step in management of a dermatomyositis patient on hydroxychloroquine and methotrexate whose skin is still active?

Muscle disease is quiescent and no other manifestations such as ILD

1 Answer available

How do you approach immunosuppression targeting skin thickening in scleroderma after the initial three years of onset?

(Skin thickening in the absence of visceral disease)

1 Answer available

What agent would you choose for a patient who needs osteoporosis therapy after a bisphosphonate holiday?

2 Answers available

How would you recommend dosing the MMR or other live vaccines for patients with rheumatoid arthritis on immunosuppressive medications such as anti-TNF alpha therapy?

For example, healthcare workers who require these vaccines for employment

1 Answer available

How do you treat Raynaud's in patients with baseline low blood pressure?

1 Answer available

How do you approach dosage changes of allopurinol as a patient's GFR decreases over time?

2 Answers available

How would you manage methotrexate therapy in an active rheumatoid arthritis patient undergoing treatment for latent TB with rifampin?

Do you stop methotrexate or adjust the dose?

1 Answer available

How do you approach the evaluation of patients referred for chronic lyme disease and counsel patients regarding this entity?

1 Answer available

When would you recommended restarting biologic medications in an active RA patient after treatment with monoclonal antibodies, convalescent plasma or antiviral medications for a COVID-19 infection?

1 Answer available

What treatment options are available for patients with spondyloarthritis who develop biologic-induced psoriasis?

1 Answer available

How do you manage arthralgias with subclinical synovitis seen on US or MRI?

1 Answer available

Do you switch to certolizumab in RA patients who are doing well on other TNFis and planning to become pregnant?

1 Answer available

Are you recommending the mRNA COVID-19 vaccines to your patients with immune mediated inflammatory diseases?

5 Answers available

Is a comprehensive physical exam with vital signs warranted for routine follow-up visits in well-controlled uncomplicated RA patients?

Reduced requirements for documentation by CMS in 2021 with respect to billing and coding have raised new questions about what aspects of physician exa...

1 Answer available

Do you assess baseline salivary gland function before starting treatment in patients with Sjogren's syndrome?

If so, what test do you use in clinical practice?

1 Answer available

Should MTX be avoided in RA patients with asymptomatic lung nodules?

If so, what would be an ideal DMARD in this setting?

1 Answer available

Do you recommend shingles vaccine to all immunosuppressed patients under the age of 50 y.o.?

1 Answer available

How do you approach patients with overlapping features of PMR and seronegative RA?

1 Answer available

How do you screen for colon cancer in patients with Behcet syndrome with colonic involvement?

1 Answer available

In what situations do you consider platelet-rich plasma injections in patients with osteoarthritis?

1 Answer available

Is it safe to use statins in IIM patients if HMGCR antibodies are negative?

1 Answer available

Are there any new treatments for erosive osteoarthritis of the hands?

1 Answer available

Do you monitor RS3PE patients for GCA with the same vigilance that you do in PMR patients?

1 Answer available

What is your first choice contraceptive agent for women with SLE?

How do you counsel these patients about hormonal agents?

1 Answer available

Should JAK inhibitors and anti-IL6 medications be avoided in patients with known diverticulosis?

2 Answers available

Should tuberculosis screening be performed before beginning methotrexate for treatment of rheumatoid arthritis?

1 Answer available

What is the typical work-up completed to rule out other conditions prior to making a diagnosis of fibromyalgia (other than history and physical exam)?

3 Answers available

How do you manage post-menopausal osteoporosis in a patient with stable bone density and no fractures after three years of holiday after giving zoledronic acid?

1 Answer available

Is it ever appropriate to initiate a higher initial dose of allopurinol (such as 300mg daily) than is typically recommended in gout patients at low risk of allopurinol hypersensitivity syndrome and severe hyperuricemia?

2 Answers available

How do you manage osteopenia, osteoporosis and calcium / Vit D supplementation in a patient with calcinosis?

1 Answer available

Do you follow patients with elevated ESR/CRP if their work-up for rheumatologic etiology is unrevealing and no other cause is identified?

2 Answers available

What are the most effective therapies for CPPD with a "pseudo-RA" pattern?

1 Answer available

Is romosozumab an option in a patient who has completed 2 years of teriparatide therapy and has a fracture while on denosumab?

1 Answer available

Does serologic activity (e.g., high titer dsDNA, low complements) without clinical disease activity in a pregnant lupus patient affect maternal or fetal outcomes?

2 Answers available

What is your approach to dental prophylaxis for patients on biologics?

1 Answer available

How long do you continue IVIG for myositis patients in remission on that therapy?

1 Answer available

When treating patients with low bone mineral density, when/how do you monitor bone turnover markers (NTX, CTX, etc)?

1 Answer available

Should methotrexate be categorically avoided in RA patients with COPD or RA-ILD?

1 Answer available

How do you manage calcium and vitamin D supplementation in patients with sarcoidosis on chronic steroids?

1 Answer available

Would you consider an osteoporosis medication in a pre-menopausal/young patient with a low Z score and an ongoing risk factor for secondary osteoporosis such as chronic antiepileptic treatment?

1 Answer available

Is there a role for tocilizumab in treatment of polymyalgia rheumatica in patients who do not have features of giant cell arteritis or rheumatoid arthritis?

1 Answer available

How do you manage severe vaginal dryness and vulvodynia refractory to topical lubricants in patients with Sjogren's syndrome?

1 Answer available

Are subcutaneous RA therapies less effective in obese patients?

1 Answer available

Is chronic major salivary gland enlargement in a patient with Sjogren's an indication for immune-modulating therapy such as hydroxychloroquine or methotrexate?

1 Answer available

How do you counsel patients who ask if there are any dietary modifications they can make to help control their autoimmune disease?

This question is part of a collaboration with RheumMadness and is specifically in reference to: ADIRA Diet

1 Answer available

How do you counsel patients who ask you about trying oral or topical formulations of medical marijuana for pain related to arthritis or fibromyalgia?

1 Answer available

What baseline work-up do you do for patients with suspected palindromic rheumatism?

1 Answer available

Is it okay to use COX-2 selective NSAIDs in patients with IBD-associated arthritis when the IBD is in remission?

1 Answer available

Do you use hydroxychloroquine for prevention of neonatal lupus in patients with a positive SSA who are planning on becoming pregnant?

1 Answer available

In which osteoporosis patients would you consider starting with anabolic therapy over antiresorptive therapy?

1 Answer available

In patients with knee osteoarthritis, do you recommend the use of hyaluronate injections if it is available and affordable for the patient?

1 Answer available

Is there a role for ultrasound in assessing for "clinically silent" inflammatory arthritis prior to tapering DMARD therapy?

1 Answer available

Do you regularly do bone density testing to screen for osteoporosis in men with rheumatoid arthritis without any other risk factors?

2 Answers available

Should patients be screened for hepatitis B/C prior to starting a conventional synthetic DMARD such as methotrexate?

1 Answer available

Papers discussed in this category

Semin. Arthritis Rheum., 2020 Mar 19

RISE registry reveals potential gaps in medication safety for new users of biologics and targeted synthetic DMARDs.

Arthritis Rheumatol, 2017 Aug

2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.

The journal of pain : official journal of the American Pain Society, 2019-06

AAPT Diagnostic Criteria for Fibromyalgia.

Arthritis care & research, 2019-03

Diagnosing Fibromyalgia as a Disease, an Illness, a State, or a Trait?

J. Rheumatol.,

Do Rheumatologists Need More Clues to Diagnose Fibromyalgia?

Current opinion in rheumatology, 2015-05

Current approaches to osteoporosis treatment.

Am J Med, 2012 Nov 20

Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.

J. Am. Coll. Cardiol.,

Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers.

Annals of the rheumatic diseases, 1999-04

Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers.

Pain, 2020 May 18

Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials.

J. Rheumatol., 2019 Jan 15

Position Statement: A Pragmatic Approach for Medical Cannabis and Patients with Rheumatic Diseases.

Rheumatology (Oxford), 2020 Feb 11

Vaginal dryness in primary Sjögren's syndrome: a histopathological case-control study.

Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica.

Clin. Rheumatol., 2017 Aug 18

Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.

Archives of internal medicine, 2008-09-22

Methotrexate is not associated with progression of interstitial lung disease in rheumatoid arthritis.

Arthritis and rheumatism, 2010-06

Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study.

Arthritis Care Res (Hoboken), 2017 Aug

2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.

Arthritis care & research, 2012-05

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

JAMA, 2006-12-27

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Arthritis & rheumatology (Hoboken, N.J.), 2016-11

Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.

Annals of the rheumatic diseases, 2019-04

Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.

Southern medical journal, 2016-11

Effects of Statin Therapy in Patients with Systemic Lupus Erythematosus.

Annals of the rheumatic diseases, 2011-05

Lupus Atherosclerosis Prevention Study (LAPS).

Atherosclerosis, 2015 Aug 28

Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study.

Ann Intern Med, 2020 Sep 22

Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study.

Osteoarthritis Cartilage, 2018 Mar 02

A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis - the HUMOR trial.

Ann Rheum Dis, 2018 Oct 03

Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial.

Ann Rheum Dis, 2018 Dec 14

Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis.

Lancet, 2019 Nov 11

Results of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial.

Annals of the rheumatic diseases, 2017-04

International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials.

Arthritis Care Res (Hoboken), 2018 Aug

Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort.

Lancet, 2015 Oct 01

Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.

Arthritis Care Res (Hoboken),

Measuring Outcomes in Psoriatic Arthritis.

J Am Dent Assoc,

Measuring salivary flow: challenges and opportunities.

Arthritis Rheumatol, 2016 Oct 26

2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts.

Ann Rheum Dis, 2019 Oct 31

EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies.

Clin Infect Dis,

Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease.

Journal of psoriasis and psoriatic arthritis, 2019-04

TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management.

Front Pharmacol, 2019 Mar 26

Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders.

The American journal of medicine, 1984-01

Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

Arthritis Rheum,

Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.

Ann Rheum Dis, 2019 Aug 14

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.

Cochrane Database Syst Rev, 2013 May 31

Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.

Ann Rheum Dis,

Antiphospholipid antibodies and infections.

Lancet Rheumatol, 2021 Apr 06

Incident systemic rheumatic disease following COVID-19.

N Engl J Med, 2020 Nov 20

Covid-19-Associated Myopathy Caused by Type I Interferonopathy.

Ann Rheum Dis, 2017 Mar 23

Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate.

The Journal of rheumatology, 2004-12

Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.

Clin Pharmacokinet,

Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Gut,

Impaired conversion of prednisone to prednisolone in patients with liver cirrhosis.

Blood,

Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance.

Annals of the rheumatic diseases, 2009-06

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

Arthritis Care Res (Hoboken), 2019 Oct

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.

Arthritis and rheumatism, 2001-12

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

The New England journal of medicine, 2003-10-16

Development of autoantibodies before the clinical onset of systemic lupus erythematosus.

Lupus, 2007

Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus.

J Allergy Clin Immunol, 2020 May 22

Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype.

Nat Rev Rheumatol,

Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis.

J Med Food,

Efficacy of Turmeric Extracts and Curcumin for Alleviating the Symptoms of Joint Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Int J Clin Pract, 2021 Apr 29

Curcumin and rheumatoid arthritis: A systematic review of literature.

Nutrients, 2020 Dec 11

Efficacy of Spice Supplementation in Rheumatoid Arthritis: A Systematic Literature Review.

Trends Mol Med, 2021 Jun 07

Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome.

Rheumatology (Oxford),

The management of Sjögren's syndrome: British Society for Rheumatology guideline scope.

Rheumatology (Oxford), 2019 Mar 05

Lymphomas complicating primary Sjögren's syndrome: from autoimmunity to lymphoma.

Chest, 2021 Feb

Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's.

J Am Dent Assoc, 2016 Jan 05

Clinical practice guidelines for oral management of Sjögren disease: Dental caries prevention.

The ocular surface, 2015 Jan 15

Clinical guidelines for management of dry eye associated with Sjögren disease.

Respir Med, 2012 Apr 09

The treatment of pulmonary sarcoidosis.

Am J Respir Crit Care Med,

Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.

Seminars in arthritis and rheumatism, 2010-12

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.

Clin Exp Rheumatol, 2012 Oct 17

Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?

Inflamm Bowel Dis,

Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.

Am J Clin Dermatol,

Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

Arthritis Rheum,

Tuberculosis associated with therapy against tumor necrosis factor alpha.

Arthritis Rheumatol, 2021 May 24

American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1.

Semin Hematol,

Epidemiology and risk factors for venous thrombosis.

Thromb Res, 2021 Jun 25

Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study.

The New England journal of medicine, 2018-03-29

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.

Rheumatology (Oxford),

Five successful pregnancies with antenatal anakinra exposure.

Z Rheumatol,

[IL-1-blockade with Anakinra during pregnancy : Retrospective analysis of efficacy and safety in female patients with familial Mediterranean fever].

Blood Adv,

American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism.

Lancet (London, England), 2015-09-19

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.

Clin Neurophysiol Pract, 2018 Apr 05

Nerve conduction studies and EMG in carpal tunnel syndrome: Do they add value?

N Engl J Med,

Bisphosphonate use and atypical fractures of the femoral shaft.

Current rheumatology reports, 2018-09-10

Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?

Nat Rev Cardiol, 2019 Jun 26

Role of aspirin in primary prevention of cardiovascular disease.

Curr Med Chem,

Targeting IL-17 and IL-23 in Immune Mediated Renal Disease.

Pathology, 2017 Mar 11

The role of interleukin-17A in the pathogenesis of kidney diseases.

Rheumatol Ther, 2021 Mar 21

Inflammatory Markers are Quickly Improved by Tocilizumab in Early Polymyalgia Rheumatica and Might Predict Early Response to Interleukin-6 Blockade.

Arthritis & rheumatology (Hoboken, N.J.), 2016-01

Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.

Ann Rheum Dis, 2021 May 28

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.

RMD Open,

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis.

Arthritis Care Res (Hoboken), 2019 Nov 29

Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study.

Semin Arthritis Rheum, 2008 Dec 31

The risk of infections with biologic therapies for rheumatoid arthritis.

Ann Intern Med, 2021 Aug 31

Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study.

Lancet, 2020 Nov 09

Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.

RMD Open, 2021 Sep

Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.

Autoimmun Rev, 2017 Sep 09

Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?

Ann Rheum Dis, 2016 Oct 03

EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.

N Engl J Med,

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.

Arthritis Rheum,

Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis.

The Journal of bone and joint surgery. American volume, 2018-04-18

Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain: A Double-Blinded, Randomized, Placebo-Controlled, Multinational Study.

Advances in therapy, 2019-06

Efficacy of Triamcinolone Acetonide Extended-Release in Participants with Unilateral Knee Osteoarthritis: A Post Hoc Analysis.

Osteoarthritis Cartilage, 2017 Oct 09

Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA).

J Bone Joint Surg Am,

An intra-articular, extended-release formulation of triamcinolone acetonide prolongs and amplifies analgesic effect in patients with osteoarthritis of the knee: a randomized clinical trial.

Trials, 2021 Nov 15

Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial.

Autoimmun Rev, 2012 Nov 30

Immunogenicity and autoimmunity during anti-TNF therapy.

Arthritis Rheum,

Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.

The New England journal of medicine, 2006-02-23

Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.

Arthritis and rheumatism, 2008-10

The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial.

Rheumatic diseases clinics of North America, 2011-02

Glucosamine and chondroitin sulfate.

Ann Rheum Dis, 2014 Jan 06

Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens.

Lupus Sci Med, 2016

Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus.

Ther Adv Musculoskelet Dis, 2022 Feb 14

Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.

Sleep Breath, 2021 Nov 12

The frequency of obstructive sleep apnea in patients with primary Sjogren's syndrome.

Rheumatol Int, 2019 Jan 02

Supervised walking improves cardiorespiratory fitness, exercise tolerance, and fatigue in women with primary Sjögren's syndrome: a randomized-controlled trial.

Lupus,

Sleep disorders and systemic lupus erythematosus.

Clin Immunol, 2020 Oct 02

Airways therapy of obstructive sleep apnea dramatically improves aberrant levels of soluble cytokines involved in autoimmune disease.

Ann Intern Med,

Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis.

Sleep,

Sex differences in obstructive sleep apnea phenotypes, the multi-ethnic study of atherosclerosis.

Worldviews Evid Based Nurs, 2017 Apr 22

The Effectiveness of Exercise in Adults With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis to Guide Evidence-Based Practice.

Ann Rheum Dis, 2020 Dec 17

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.

Eur J Dermatol,

Use of anti-IL 17A for psoriasis is not necessarily contraindicated in organ transplantation patients.

Dermatol Ther, 2019 Apr 23

Treatment of severe psoriasis with ixekizumab in a liver transplant recipient with concomitant hepatitis B virus infection.

Cutis,

Brodalumab in an Organ Transplant Recipient With Psoriasis.

Arthritis and rheumatism, 2013-07

Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio.

Am J Clin Dermatol,

Bullous systemic lupus erythematosus: a review and update to diagnosis and treatment.

Arthritis care & research, 2014-08

Identification of risk factors for elevated transaminases in methotrexate users through an electronic health record.

Intern Med J, 2022 Mar 16

Assessment of liver fibrosis markers in people with rheumatoid arthritis on methotrexate.

The New England journal of medicine, 2013-08-01

Efficacy of remission-induction regimens for ANCA-associated vasculitis.

Ann. Rheum. Dis., 2017 May 25

Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.

N Engl J Med,

Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.

N Engl J Med,

Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.

Ann Rheum Dis, 2016 Feb 17

The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.

Support Care Cancer, 2019 Dec 13

Effects of ginger adjunct to the standard prophylaxis on reducing carboplatin and paclitaxel-induced nausea vomiting: a randomized controlled study.

Rheumatol Int, 2014 Jun 05

Identification of lymphoma predictors in patients with primary Sjögren's syndrome: a systematic literature review and meta-analysis.

J Rheumatol, 2017 May 15

Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.

Int J Rheum Dis, 2018 Sep 05

Long-term patient reported outcomes of elbow, wrist and hand surgery for rheumatoid arthritis.

Rheumatol Ther, 2020 Dec 24

Renal Disease in Primary Sjögren's Syndrome.

Medizinische Klinik (Munich, Germany : 1983), 2002-11-15

[Prevalence of circulating autoantibodies in healthy individuals].

Journal for scientific research. Medical sciences, 2001 Apr

Occurence of autoantibodies in healthy Omani individuals.

Diagnosis and Management of the Antiphospholipid Syndrome.

Lupus Sci Med, 2018 Sep 25

Obstetric antiphospholipid syndrome.

Journal of the American Academy of Dermatology, 2011-05

Quality of life in cutaneous lupus erythematosus.

Lupus, 2016 May 27

Cutaneous lupus erythematosus and systemic lupus erythematosus are associated with clinically significant cardiovascular risk: a Danish nationwide cohort study.

Clin Exp Rheumatol, 2013 Aug 02

Pain and pruritus in cutaneous lupus: their association with dermatologic quality of life and disease activity.

J Rheumatol, 2022 Aug 01

Timing and Predictors of Incident Cardiovascular Disease in Systemic Lupus Erythematosus: Risk Occurs Early and Highlights Racial Disparities.

N Engl J Med, 2003 Feb 13

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Metabolites, 2022 Nov 05

Nonalcoholic Fatty Liver Disease-A Concise Review of Noninvasive Tests and Biomarkers.

J Rheumatol, 2022 Mar 15

Using FibroScan to Assess for the Development of Liver Fibrosis in Patients With Arthritis on Methotrexate: A Single-center Experience.

J Clin Densitom, 2020 Dec 13

Bone Turnover Markers: A New Year Resolution?

J Clin Endocrinol Metab, 2020 May 01

Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society.

Lupus, 2019 Jun 19

Prognostic markers of lymphoma development in primary Sjögren syndrome.

Ann Rheum Dis, 2011 Nov 09

Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjogren's syndrome in Taiwan.

The Journal of rheumatology, 2012-01

Combination biologic treatment of refractory psoriasis and psoriatic arthritis.

JAAD Case Rep, 2019 Oct 10

Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis.

Current medical research and opinion, 2016-12

Corticosteroids: the knee jerk response.

Open access rheumatology : research and reviews, 2016

Polymyalgia rheumatica: observations of disease evolution without corticosteroid treatment.

Arthritis Care Res (Hoboken), 2022 Aug 04

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.

JAMA dermatology, 2018-10-01

Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis.

Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers.

Archives of dermatology, 2002 Sep

Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus.

Arthritis and rheumatism, 2008-09

Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2014-12

Curr Rheumatol Rep, 2022 Feb 15

Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response.

Arthritis Care Res (Hoboken), 2017 Dec

Impact of Obesity and Adiposity on Inflammatory Markers in Patients With Rheumatoid Arthritis.

JAMA, 1999 Dec 08

Elevated C-reactive protein levels in overweight and obese adults.

Reumatologia, 2020 Feb 28

The impact of obesity on inflammatory markers used in the assessment of disease activity in rheumatoid arthritis - a cross-sectional study.

The lancet. Diabetes & endocrinology, 2017-07

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.

Lupus Sci Med, 2021 Jan

Apolipoprotein L1 risk genotypes in Ghanaian patients with systemic lupus erythematosus: a prospective cohort study.

Rheumatology (Oxford, England), 2018-09-01

The SLE-key test serological signature: new insights into the course of lupus.

Lupus, 2021 Jan 05

Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: Cross sectional analysis of the LuLa cohort.

Arthritis Rheumatol, 2018 Jun 27

Brief Report: Lupus-An Unrecognized Leading Cause of Death in Young Females: A Population-Based Study Using Nationwide Death Certificates, 2000-2015.

J Manag Care Spec Pharm, 2022 Jul 01

Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus.

Diagnostics (Basel), 2021 Sep 01

Anti-DFS70 Antibodies for Differentiating Systemic Autoimmune Rheumatic Disease in Patients with Positive ANA Tests: A Systematic Review and Meta-Analysis.

Front Immunol, 2021 May 27

Autoantibody Discovery, Assay Development and Adoption: Death Valley, the Sea of Survival and Beyond.

Expert review of clinical immunology, 2015 Dec 22

Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations.

The neurologist, 2017 Jul

Spectrum of Autonomic Nervous System Impairment in Sjögren Syndrome.

Arthritis care & research, 2012-10

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.

Joint Bone Spine, 2015 Dec 18

Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment.

Arthritis Rheumatol, 2020 Apr

2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.

Autoimmunity reviews, 2017-09

Clinical and pathologic implications of extending the spectrum of maternal autoantibodies reactive with ribonucleoproteins associated with cutaneous and now cardiac neonatal lupus from SSA/Ro and SSB/La to U1RNP.

AACE Clin Case Rep, 2020 Aug 06

METHOTREXATE TREATMENT FOR SARCOIDOSIS-INDUCED HYPERCALCEMIA.

Am J Med, 1987 Jun

Hydroxychloroquine treatment of hypercalcemia in a patient with sarcoidosis undergoing hemodialysis.

Sarcoidosis Vasc Diffuse Lung Dis, 2012 Mar

Hypercalcemia from sarcoidosis successfully treated with infliximab.

Arch Osteoporos, 2017 Jul 19

Glucocorticoid sparing effect of zoledronic acid in sarcoid hypercalcemia.

BMJ Case Rep, 2022 Jul 08

Hungry bone syndrome like presentation following single-dose denosumab for hypercalcaemia secondary to sarcoidosis with IgA nephropathy.

Arthritis Res Ther, 2014 Mar 24

Bone fragility in sarcoidosis and relationships with calcium metabolism disorders: a cross sectional study on 142 patients.

Neurology, 2017-11-14

Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series.

Neurol Neuroimmunol Neuroinflamm, 2020 Jul 27

Infliximab treatment in pathology-confirmed neurosarcoidosis.

Arthritis research & therapy, 2013-02-01

Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.

Arthritis Rheumatol, 2021 Jul 07

A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares.

Ann Rheum Dis, 2012 May 14

Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.

Mol Biol Rep, 2021 Jun 01

The role of Interleukin-1 receptor antagonist as a treatment option in calcium pyrophosphate crystal deposition disease.

Curr Rheumatol Rep, 2014 Feb

Anti-interleukin-1 therapy in the management of gout.

Pharmacotherapy, 2013 Apr 03

Role of interleukin-1 inhibitors in the management of gout.

Int J Environ Res Public Health, 2021 Aug 01

Relationship of Hydroxychloroquine and Ophthalmic Complications in Patients with Type 2 Diabetes in Taiwan.

Arthritis and rheumatism, 2008-11

Resolution of gouty tophi after twelve weeks of pegloticase treatment.

Arthritis Rheumatol, 2020 Jan

Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits.

Arthritis Care Res (Hoboken), 2020 May 11

2020 American College of Rheumatology Guideline for the Management of Gout.

Arthritis Rheum, 2002 Aug

Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.

JAMA, 2011-08-17

Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.

Arthritis Rheumatol, 2022 Dec 16

A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings.

Journal of clinical lipidology, 2008-10

Curr Rheumatol Rep, 2020 Aug 26

Lipid-lowering Therapies in Myositis.

Arthritis & rheumatology (Hoboken, N.J.), 2017-10

The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.

Current rheumatology reviews, 2019

Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.

Am J Clin Dermatol, 2022 Jun 23

Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review.

J Rheumatol, 2020 Apr 01

Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort.

J Rheumatol, 2022 Oct 15

Isolated Neutropenia in Systemic Lupus Erythematosus.

J Rheumatol, 2006 Jul 01

Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares.

Lupus science & medicine, 2018

Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE.

BMC Rheumatol, 2021 Oct 01

Retinopathy in newly-diagnosed systemic lupus erythematosus: should we screen for ocular involvement?

Clin Ophthalmol, 2011 Oct 04

Isolated cotton-wool spots of unknown etiology: management and sequential spectral domain optical coherence tomography documentation.

Journal of immunology (Baltimore, Md. : 1950), 2004-08-15

Complete complement components C4A and C4B deficiencies in human kidney diseases and systemic lupus erythematosus.

Autoimmunity reviews, 2009-02

The risk of ultraviolet radiation exposure from indoor lamps in lupus erythematosus.

Lupus science & medicine, 2017

Cell-bound complement activation products in SLE.

Arthritis care & research, 2019-01

Obesity is Independently Associated With Worse Patient-Reported Outcomes in Women with Systemic Lupus Erythematosus.

Lupus, 2018-08

Less than 7 hours of sleep per night is associated with transitioning to systemic lupus erythematosus.

Arthritis Rheumatol, 2021 May 02

Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus.

Arthritis Rheum,

Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus.

Arthritis Rheumatol, 2020 Jan 07

Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.

Arthritis Rheumatol, 2014 Sep

Establishment of gene copy number-specific normal ranges for serum C4 and its utility for interpretation in patients with chronically low serum C4 concentrations.

Arthritis Care Res (Hoboken), 2012 Apr

Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period.

Lupus, 2022 Jan 23

The association between lupus serology and disease outcomes: A systematic literature review to inform the treat-to-target approach in systemic lupus erythematosus.

Arthritis Care Res (Hoboken), 2022 Dec 20

Perceived Stress and Prediction of Worse Disease Activity and Symptoms in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort.

Nat Rev Nephrol, 2015 Nov 16

Renal involvement in primary Sjögren syndrome.

Ear Nose Throat J, 2015 Jun

Intraductal infusion of steroids in patients with Sjögren syndrome to treat painful salivary swelling: Report of 2 cases.

Oral Dis, 2021 Mar 12

Eosinophilic sialodochitis: An emerging atopic condition.

Oral Dis, 2016 Dec 06

Eosinophilic sialodochitis: redefinition of 'allergic parotitis' and 'sialodochitis fibrinosa'.

JAMA, 2019 Apr 16

Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain: The Alliance A221304 Randomized Clinical Trial.

Head Neck, 2016 Mar 29

Effectiveness of honey on radiation-induced oral mucositis, time to mucositis, weight loss, and treatment interruptions among patients with head and neck malignancies: A meta-analysis and systematic review of literature.

The Lancet. Oncology, 2017-05

Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.

Ann Rheum Dis, 2022 Oct 05

Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports.

Ann Rheum Dis, 2023 Jan 05

Transplacental passage of belimumab during pregnancy and follow-up of a child exposed in utero.

Lupus, 2022 Nov 30

Dilemma of belimumab therapy (dis)continuation during pregnancy: Results of a retrospective study in eudravigilance.

BMJ, 2023 May 30

Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK.

BMJ, 2023 May 30

Monitoring methotrexate toxicity: Are we being over-vigilant?

The lancet. Diabetes & endocrinology, 2019 Aug 22

Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial.

Arthritis Rheum, 1972 Mar-Apr

The influence of temperature on the solubility of monosodium urate.

Arthritis Rheumatol, 2023 Mar 10

Amplification of Inflammation by Lubricin Deficiency Implicated in Incident, Erosive Gout Independent of Hyperuricemia.

Clinical rheumatology, 1988 Sep

Treatment of psoriatic arthritis with sulphasalazine: a one year open study.

Journal of the American Academy of Dermatology, 1987 Apr

Gold therapy and its indications in dermatology. A review.

Journal of the American Academy of Dermatology, 2020 May 19

Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment.

Ann Rheum Dis, 2021 Sep 07

Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases.

Arthritis research & therapy, 2023 Nov 20

Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review.

RMD open, 2021 Jul

Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study-a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial.

Arthritis research & therapy, 2021 Jul 08

Identification and prediction of difficult-to-treat rheumatoid arthritis patients in structured and unstructured routine care data: results from a hackathon.

The New England journal of medicine, 2018 Oct 01

Fracture Prevention with Zoledronate in Older Women with Osteopenia.

Arthritis and rheumatism, 2012-07

Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies.

Annals of the rheumatic diseases, 2018-09

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.

Arthritis & rheumatology (Hoboken, N.J.), 2019-02

Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.

RMD open, 2020 Feb

Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials.

The New England journal of medicine, 2014 Jun 05

Once-weekly dalbavancin versus daily conventional therapy for skin infection.

Trials, 2022 Sep 05

Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.

Arthritis Care Res (Hoboken), 2016 Jan

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Alimentary pharmacology & therapeutics, 2022 May 20

Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management.

BMC nephrology, 2019 Oct 31

Clinical practice guideline on pregnancy and renal disease.

Blood, 2011-02-03

Pregnancy outcomes after maternal exposure to rituximab.

Arthritis Care Res (Hoboken), 2020 Apr

2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.

Lupus, 2019-05

Photosensitivity and photoprotection in patients with lupus erythematosus.

Journal of the American Academy of Dermatology, 2020 Apr 28

Cosmetic treatment in patients with autoimmune connective tissue diseases: Best practices for patients with lupus erythematosus.

The British journal of dermatology, 2003 Jul

Photosensitivity in patients with lupus erythematosus: a clinical and photobiological study of 100 patients using a prolonged phototest protocol.

Annals of the rheumatic diseases, 2011 Sep 16

Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry.

The New England journal of medicine, 2023 Oct 05

Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.

Ann Rheum Dis, 2015 Oct

2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.

JAMA, 2022 Sep 20

Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.

Arthritis care & research, 2023 Oct 26

2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.

Rheumatology advances in practice, 2021 Nov 27

Fragility fractures and prescriptions of medications for osteoporosis in patients with polymyalgia rheumatica: results from the PMR Cohort Study.

Arteriosclerosis, thrombosis, and vascular biology, 2019-07

Cardiovascular Outcomes of Romosozumab and Protective Role of Alendronate.

JAMA ophthalmology, 2014-12

The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy.

Arthritis Care Res (Hoboken), 2021 Mar 30

Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.

Lupus, 2017 Sep 01

Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus.

Lupus science & medicine, 2023 Nov 22

Genotype-guided new approach for dose optimisation of hydroxychloroquine administration in Chinese patients with SLE.

Arthritis research & therapy, 2020 Sep 25

Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence.

Osteoarthritis and cartilage open, 2023 Feb 06

Genicular artery embolization for treatment of knee osteoarthritis pain: Systematic review and meta-analysis.

British journal of rheumatology, 1992 Nov

Injection therapy of superficial rheumatoid nodules.

Pharmacotherapy, 2002-09

A review of methotrexate-induced accelerated nodulosis.

Medicine, 2001 Jul

The HLA-DRB1*0401 allele and the development of methotrexate-induced accelerated rheumatoid nodulosis: a follow-up study of 79 Caucasian patients with rheumatoid arthritis.

American journal of respiratory and critical care medicine, 2015 Jul 15

Methotrexate-induced Accelerated Pulmonary Nodulosis.

Autoimmunity reviews, 2017 Feb 13

Antiphospholipid antibodies disappearance in primary antiphospholipid syndrome: Thrombosis recurrence.

Thrombosis research, 2023 Feb 10

Recurrent thrombotic events after disappearance of antiphospholipid autoantibodies: A long-term longitudinal study in patients with antiphospholipid syndrome.

Lupus, 2017 Mar 29

Cessation of oral anticoagulants in antiphospholipid syndrome.

International journal of clinical pharmacology and therapeutics, 2014 Jan

Assessment of disease-drug-drug interaction between single-dose tocilizumab and oral contraceptives in women with active rheumatoid arthritis.

Ann Rheum Dis, 2022 Jan 13

Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study.

BMC musculoskeletal disorders, 2016-08-24

The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis.

Clinical journal of the American Society of Nephrology : CJASN, 2017-05-08

Update on Lupus Nephritis.

Ann Rheum Dis, 2014 Feb 13

The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort.

Annals of the rheumatic diseases, 2023 Oct 12

EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.

Arthritis & rheumatology (Hoboken, N.J.), 2023 Jun 25

"Burnout" Coupled with Workforce Shortages Spells Trouble: Innovative Solutions Are Essential for More Satisfying Rheumatology Practice.

Modern rheumatology, 2020 Jun 16

Which is the best SLE activity index for clinical trials?

Arthritis care & research, 2023 Nov 28

Reference Range of Hydroxychloroquine Blood Levels That Can Reduce Odds of Active Lupus and Prevent Flares.

Current opinion in rheumatology, 2014-03

Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature.

Rheumatology (Oxford, England), 2013 Feb 04

Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine.

Current opinion in rheumatology, 2018 Jul

Trimethoprim-sulfamethoxazole and antineutrophil cytoplasmic antibodies-associated vasculitis.

European journal of medical research, 2009 Dec 07

Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement.

Annals of the rheumatic diseases, 2018 Jun 27

Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis.

Science (New York, N.Y.), 1982-04-23

Systemic lupus erythematosus-like syndrome in monkeys fed alfalfa sprouts: role of a nonprotein amino acid.

Arthritis care & research, 2017-03

Influence of Alcohol Consumption on the Risk of Systemic Lupus Erythematosus Among Women in the Nurses' Health Study Cohorts.

Arthritis & rheumatology (Hoboken, N.J.), 2017-11

Association of Trauma and Posttraumatic Stress Disorder With Incident Systemic Lupus Erythematosus in a Longitudinal Cohort of Women.

Cell host & microbe, 2019-01-09

A Diet-Sensitive Commensal Lactobacillus Strain Mediates TLR7-Dependent Systemic Autoimmunity.

Lupus, 2018 Oct 11

Pesticide exposure and risk of systemic lupus erythematosus in an urban population of predominantly African-American women.

Arthritis care & research, 2022 Oct 11

Association of Healthy Lifestyle Behaviors and the Risk of Developing Rheumatoid Arthritis Among Women.

BMJ (Clinical research ed.), 2022 Jan 26

Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial.

Clinical and experimental immunology, 2003 Mar

Silica accelerated systemic autoimmune disease in lupus-prone New Zealand mixed mice.

Environmental health perspectives, 2005 Dec

Phthalate linked to lupus in mice.

Lupus, 2001

Diet and systemic lupus erythematosus: from mouse and monkey to woman?

Auto- immunity highlights, 2012 Jan 13

Hair dyes as a risk for autoimmunity: from systemic lupus erythematosus to primary biliary cirrhosis.

Rheumatic diseases clinics of North America, 2006 Feb

Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosus.

The New England journal of medicine, 1986 Mar 06

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2003

Abetimus: Abetimus sodium, LJP 394.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015-08-01

Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 cases.

BMC public health, 2008 Jan 21

The SMILE study: a study of medical information and lifestyles in Eindhoven, the rationale and contents of a large prospective dynamic cohort study.

Arthritis & rheumatology (Hoboken, N.J.), 2017-03

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.

Annals of the rheumatic diseases, 2019 Jul 30

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.

Annals of the rheumatic diseases, 2024 Mar 18

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.

The Lancet. Rheumatology, 2024 Apr 04

Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.

Rheumatology (Oxford, England), 2023 Oct 19

A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (RHEUMTAP) cohort.

JAMA, 2021 May 04

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial.

Joint bone spine, 2021 May 19

Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis.

Kidney international, 2024 Jan

KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS.

Lupus, 2023 Sep 27

Repeat kidney biopsy findings of lupus nephritis patients in clinical remission treated with Mycophenolate associated with Belimumab or Mycophenolate plus standard of care therapy. A "post-hoc" analysis of participants in the BLISS-LN and open label extension study belonging to a single center.

Arthritis & rheumatology (Hoboken, N.J.), 2023 Jul 19

Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial.

Clin Rheumatol, 2021 Apr

Systematic review of recommendations on the use of methotrexate in rheumatoid arthritis.

Annals of the rheumatic diseases, 2001 May

Acute arthritis after intra-articular hyaluronate injection: onset of effusions without crystal.

The Journal of rheumatology, 1997 May

Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis.

British journal of rheumatology, 1995 May

Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients.

Lancet (London, England), 2025 Jan 25

Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial.

Lupus, 2014 Jul 30

Serious infections in systemic lupus erythematosus with a focus on pneumococcal infections.

MMWR. Morbidity and mortality weekly report, 2024 Sep 12

Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024.

Journal of the Endocrine Society, 2022 Dec 02

Perioperative Evaluation and Management of Patients on Glucocorticoids.

Diagnostics (Basel, Switzerland), 2021 Apr 20

Glucocorticoid Withdrawal-An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice.

Arthritis care & research, 2016 Jan

Vitamin D Supplementation in Adolescents and Young Adults With Juvenile Systemic Lupus Erythematosus for Improvement in Disease Activity and Fatigue Scores: A Randomized, Double-Blind, Placebo-Controlled Trial.

Lupus, 2014 Feb 06

Vitamin D and cutaneous lupus erythematosus: effect of vitamin D replacement on disease severity.

Journal of the American Academy of Dermatology, 2015 Jan 30

Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2016 Dec 20

S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV).

Proceedings of the National Academy of Sciences of the United States of America, 2005 Mar 02

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.

Autoimmunity reviews, 2023 Dec 20

Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study.

The New England journal of medicine, 2005-12-15

Combined oral contraceptives in women with systemic lupus erythematosus.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2023 Jul 01

Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging.

Expert review of anticancer therapy, 2009-01

The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.

Lancet Gastroenterol Hepatol, 2023 Feb 01

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.

Clinical transplantation, 2020 Nov 22

Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data.

Clinical and experimental immunology, 2015 Apr

Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study.

JAMA internal medicine, 2017 Nov 01

Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.

Annals of the rheumatic diseases, 2024 Jan 11